HC Wainwright Reaffirms Buy Rating for Abeona Therapeutics (NASDAQ:ABEO)

HC Wainwright restated their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a report released on Monday morning, MarketBeat.com reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Abeona Therapeutics’ Q1 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($1.11) EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.05 EPS and FY2026 earnings at ($0.12) EPS.

Other equities analysts also recently issued reports about the stock. StockNews.com downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 22nd. Oppenheimer assumed coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Abeona Therapeutics has an average rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Stock Down 0.2 %

ABEO opened at $4.99 on Monday. The company has a market cap of $216.92 million, a P/E ratio of -1.86 and a beta of 1.79. Abeona Therapeutics has a 12 month low of $3.05 and a 12 month high of $8.45. The business’s 50-day moving average price is $5.43 and its 200-day moving average price is $5.82. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.19. On average, equities analysts expect that Abeona Therapeutics will post -1.16 EPS for the current year.

Institutional Trading of Abeona Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Twinbeech Capital LP purchased a new position in shares of Abeona Therapeutics during the 4th quarter worth approximately $58,000. Northern Trust Corp boosted its position in shares of Abeona Therapeutics by 6.6% during the fourth quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company’s stock valued at $1,030,000 after purchasing an additional 11,478 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Abeona Therapeutics during the fourth quarter valued at approximately $67,000. Jane Street Group LLC purchased a new stake in Abeona Therapeutics in the third quarter worth $84,000. Finally, Oxford Asset Management LLP bought a new position in Abeona Therapeutics in the fourth quarter worth $118,000. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.